Excessive Daytime Sleepiness — Symptoms, Causes & Treatment | MyMedicPlus

Excessive daytime sleepiness (EDS) is defined as the inability to maintain wakefulness and alertness during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times — despite an apparently adequate or even prolonged night-time sleep opportunity. EDS differs from normal tiredness in its pathological severity, persistence, and functional impairment. It affects approximately 10–20% of the adult general population and represents one of the most common complaints in sleep medicine practice, accounting for up to 40% of referrals to specialist sleep centres. The Epworth Sleepiness Scale (ESS) — an 8-item validated self-report questionnaire where patients rate their likelihood of dozing in everyday situations (total score 0–24; above 10 indicates pathological sleepiness) — is the standard clinical screening tool. EDS significantly impairs cognitive performance (attention, working memory, executive function), reduces work productivity, and substantially increases the risk of road traffic accidents — drowsy driving is responsible for approximately 20% of fatal motor vehicle accidents in high-income countries. Critically, EDS is a symptom rather than a diagnosis — the underlying cause must be identified to guide effective treatment. The most common underlying cause is obstructive sleep apnoea (OSA), which is markedly underdiagnosed, followed by insufficient sleep syndrome, narcolepsy, and idiopathic hypersomnia.

Obstructive sleep apnoea (OSA) is the most common cause — affecting 15–30% of adults (50% of men over 65), with repetitive complete (apnoea) or partial (hypopnoea) upper airway collapse during sleep causing arousal micro-events that fragment sleep architecture and prevent restorative deep (slow-wave) and REM sleep. OSA is defined by an apnoea-hypopnoea index (AHI) above 5 events/hour on polysomnography. Insufficient sleep syndrome (behaviorally induced insufficient sleep): chronic sleep restriction from social, occupational, or family pressures — the single most prevalent cause of EDS in the general population; adults require 7–9 hours per night. Narcolepsy type 1 (with cataplexy): autoimmune destruction of hypothalamic hypocretin (orexin)-producing neurons (CSF hypocretin-1 below 110 pg/mL — the diagnostic biomarker) causes irresistible sleep attacks, cataplexy (sudden bilateral muscle weakness triggered by emotion — emotion-triggered tone loss without loss of consciousness, distinguishing it from syncope or seizure), sleep paralysis, and hypnagogic hallucinations. Narcolepsy type 2 (without cataplexy): similar symptoms without cataplexy and with normal or intermediate CSF hypocretin. Idiopathic hypersomnia: prolonged major sleep episode (above 9 hours), difficulty waking (sleep inertia — severe 'sleep drunkenness'), and EDS without REM dysregulation — recent evidence implicates GABA potentiation via a circulating somnogen; claritromycin and flumazenil show promise. Circadian rhythm sleep-wake disorders: shift work disorder (EDS during required waking hours in shift workers — affects 10% of night workers); delayed sleep-wake phase disorder (DSWPD — inability to fall asleep or wake at conventional times); jet lag. Medical causes: hypothyroidism, anaemia, chronic kidney disease, heart failure, stroke, Parkinson's disease, myotonic dystrophy, and depression. Medications: sedating antihistamines, benzodiazepines, Z-drugs, opioids, tricyclic antidepressants, first-generation antipsychotics, antiepileptics (especially phenobarbital, primidone, gabapentin), and beta-blockers.

The hallmark symptom is difficulty maintaining wakefulness and alertness during intended waking hours, despite adequate or excessive night-time sleep. This manifests as: unintentional napping during sedentary activities (watching television, reading, travelling as a passenger), difficulty sustaining attention in meetings or conversations, automatic behaviour (performing routine actions without conscious awareness — driving familiar routes 'on autopilot' with no memory of portions of the journey), and slow reaction times. Morning headache (particularly in OSA — from nocturnal hypercapnia and hypoxaemia) and unrefreshing sleep (characteristic of OSA, idiopathic hypersomnia, and fibromyalgia-associated sleep dysfunction). Cognitive symptoms: impaired working memory, reduced attention span, executive function deficits, and slowed information processing — often initially misattributed to ageing, depression, or motivational problems. Microsleeps: involuntary sleep episodes lasting 2–30 seconds that the person is unaware of during the episode — particularly dangerous during driving; associated with lane deviation and failure to brake in simulator studies. Narcolepsy-specific symptoms: cataplexy (sudden loss of muscle tone triggered by laughter, surprise, anger, or excitement — ranges from jaw drop or head nod to complete postural collapse; preserved consciousness throughout — a key differentiating feature); sleep paralysis (transient inability to move during sleep-wake transition, lasting seconds to minutes); hypnagogic hallucinations (vivid, often frightening visual or auditory hallucinations at sleep onset or awakening); fragmented nocturnal sleep (counterintuitively, narcoleptics often have disrupted night-time sleep).

A systematic approach to diagnosing the underlying cause of EDS is essential. Clinical history: ESS score; sleep diary or actigraphy (wrist-worn accelerometer worn for 2 weeks — objective sleep-wake estimation); work and lifestyle history (shift work, travel, social obligations); medications; mood and mental health screening; partner-reported snoring, witnessed apnoeas, or abnormal movements. Overnight polysomnography (PSG): the gold standard investigation — multi-channel recording of EEG, EOG (eye movements), EMG (chin and limb muscles), nasal airflow (thermistor and pressure transducer), thoracic and abdominal respiratory effort, oximetry, ECG, body position, and video. Diagnoses: OSA (AHI above 5 in an appropriate clinical context), periodic limb movement disorder (PLMD), narcolepsy-related REM behaviour disorder, and central sleep apnoea. The Multiple Sleep Latency Test (MSLT): performed the day after overnight PSG following adequate prior sleep (confirmed by PSG and 2-week actigraphy); the patient has 4–5 daytime nap opportunities in a dark, quiet room at 2-hour intervals — mean sleep latency (MSL) is calculated; MSL below 8 minutes confirms pathological EDS; two or more sleep-onset REM periods (SOREMPs) during MSLT (or one SOREMP on PSG) plus clinical symptoms confirms narcolepsy type 1 or 2. CSF hypocretin-1 measurement (via lumbar puncture): below 110 pg/mL is a diagnostic biomarker for narcolepsy type 1 (hypocretin deficiency). Home sleep apnoea testing (HSAT/type 3 portable monitor): validated for diagnosis of moderate-to-severe OSA in appropriate clinical settings — measures airflow, effort, and oximetry without EEG; AHI derived from recording time (rather than total sleep time) means HSAT underestimates OSA severity. Thyroid function, FBC, ferritin (restless legs), fasting glucose (metabolic causes).

Treatment is fundamentally directed at the underlying cause. Obstructive sleep apnoea: Continuous positive airway pressure (CPAP) — the gold standard treatment for moderate-to-severe OSA — provides a pneumatic splint maintaining airway patency; EDS resolves in CPAP-compliant patients (above 4 hours/night) within weeks; ESS typically falls by 3–4 points. Mandibular advancement device (MAD) — a custom dental appliance advancing the lower jaw to increase the retropalatal airway — is recommended for mild-to-moderate OSA, CPAP-intolerant patients, and positional OSA. Weight loss of 10% reduces AHI by approximately 30–40% in obese OSA patients. Upper airway surgery (uvulopalatopharyngoplasty — UPPP, tongue-base procedures, maxillomandibular advancement) is appropriate for selected anatomical causes. Insufficient sleep: structured sleep extension programme targeting 7–9 hours per night; sleep hygiene education; cognitive behavioural therapy for insomnia (CBT-I) if coexisting insomnia prevents adequate sleep duration. Narcolepsy: Sodium oxybate (Xyrem/Lumryz — gamma-hydroxybutyrate): the most effective treatment for both EDS and cataplexy in narcolepsy — taken as a nightly dose at bedtime and a second dose 2.5–4 hours later; classified as a controlled substance. Modafinil (200–400 mg/day) and armodafinil (150–250 mg/day): wakefulness-promoting agents acting on noradrenaline and dopamine pathways — first-line for residual EDS in narcolepsy when sodium oxybate is insufficient or not tolerated. Pitolisant (Wakix): histamine H3 receptor antagonist/inverse agonist — approved for narcolepsy EDS and cataplexy; non-controlled. Methylphenidate, dexamfetamine: stimulants used in narcolepsy refractory to other treatments. Idiopathic hypersomnia: sodium oxybate; clarithromycin (off-label — inhibits GABA potentiation). Shift work disorder: melatonin (0.5–5 mg) before daytime sleep; modafinil before night shifts.

Drowsy driving is the most immediately life-threatening complication of EDS — it is responsible for approximately 20% of fatal road traffic accidents; the impairment caused by 17 hours of wakefulness is equivalent to a blood alcohol level of 0.05%, and 24 hours of wakefulness is equivalent to 0.10% BAC. Drowsy drivers have slower reaction times, reduced vigilance, longer braking distances, and are more likely to run off the road. In the UK and many other countries, it is a legal offence to drive while impaired by sleepiness; medical professionals have a duty of care to advise patients not to drive until EDS is adequately controlled. Untreated OSA-associated EDS carries significant cardiovascular risk — sleep apnoea is independently associated with hypertension (50% of OSA patients; 30% of hypertension patients have OSA), atrial fibrillation (2-fold increased risk), stroke (up to 4-fold increased risk), heart failure, and type 2 diabetes — in part mediated through chronic intermittent hypoxia, sympathetic nervous system activation, and systemic inflammation. Occupational accidents: EDS impairs psychomotor performance, reaction times, and decision-making — industrial and occupational accidents involving heavy machinery, air traffic control, surgery, and high-risk occupations are substantially associated with operator fatigue and EDS. Cognitive decline: chronic EDS from untreated OSA is associated with increased risk of dementia (mild cognitive impairment and Alzheimer's disease — hypoxia-induced tau phosphorylation and amyloid deposition).

Prioritize adequate and consistent sleep of 7–9 hours per night for adults. Maintain a regular sleep-wake schedule including on weekends. Avoid alcohol and heavy meals close to bedtime. Treat sleep apnea with CPAP and achieve a healthy body weight to reduce OSA severity. If you must drive long distances, take a 20-minute nap before driving and stop every 2 hours. Never drive if feeling sleepy. Report EDS to your doctor proactively, as it significantly impairs safety and quality of life but is highly treatable when properly diagnosed.

See your GP urgently if you have fallen asleep while driving, or have had a near-miss due to sleepiness — you should not drive until assessed and treated. Seek prompt evaluation if your Epworth Sleepiness Scale (ESS) score is above 10, as this indicates pathological sleepiness requiring investigation. Book a GP appointment within 2 weeks if you are regularly falling asleep in inappropriate situations (during a conversation, at work, while eating), if you snore heavily or have been told you stop breathing during sleep (suggesting obstructive sleep apnea), or if your partner has noticed episodes of sudden muscle weakness triggered by laughter or surprise (possible cataplexy — narcolepsy). Refer to a sleep medicine specialist if: polysomnography confirms obstructive sleep apnea but CPAP therapy fails to resolve EDS; or if narcolepsy is suspected based on clinical history — MSLT confirmation and specialist-initiated medications (sodium oxybate, modafinil) are required. Report EDS to your employer and DVLA/FMCSA if legally required in your country before resuming safety-critical work or driving.